JP2024500324A5 - - Google Patents

Info

Publication number
JP2024500324A5
JP2024500324A5 JP2023534386A JP2023534386A JP2024500324A5 JP 2024500324 A5 JP2024500324 A5 JP 2024500324A5 JP 2023534386 A JP2023534386 A JP 2023534386A JP 2023534386 A JP2023534386 A JP 2023534386A JP 2024500324 A5 JP2024500324 A5 JP 2024500324A5
Authority
JP
Japan
Prior art keywords
approximately
use according
pharmaceutical
weeks
dosage formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023534386A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024500324A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/062286 external-priority patent/WO2022125598A1/en
Publication of JP2024500324A publication Critical patent/JP2024500324A/ja
Publication of JP2024500324A5 publication Critical patent/JP2024500324A5/ja
Pending legal-status Critical Current

Links

JP2023534386A 2020-12-07 2021-12-07 Glp-1rおよびgcgr均衡アゴニストを使用した血糖および/または体重を低下させるための治療レジメンおよび方法 Pending JP2024500324A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063122117P 2020-12-07 2020-12-07
US63/122,117 2020-12-07
US202163211157P 2021-06-16 2021-06-16
US63/211,157 2021-06-16
US202163249468P 2021-09-28 2021-09-28
US63/249,468 2021-09-28
PCT/US2021/062286 WO2022125598A1 (en) 2020-12-07 2021-12-07 Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists

Publications (2)

Publication Number Publication Date
JP2024500324A JP2024500324A (ja) 2024-01-09
JP2024500324A5 true JP2024500324A5 (cg-RX-API-DMAC7.html) 2024-11-20

Family

ID=81972768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023534386A Pending JP2024500324A (ja) 2020-12-07 2021-12-07 Glp-1rおよびgcgr均衡アゴニストを使用した血糖および/または体重を低下させるための治療レジメンおよび方法

Country Status (8)

Country Link
US (1) US20250134963A1 (cg-RX-API-DMAC7.html)
EP (1) EP4255564A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024500324A (cg-RX-API-DMAC7.html)
KR (1) KR20230129425A (cg-RX-API-DMAC7.html)
CA (1) CA3201539A1 (cg-RX-API-DMAC7.html)
IL (1) IL303512A (cg-RX-API-DMAC7.html)
MX (1) MX2023006736A (cg-RX-API-DMAC7.html)
WO (1) WO2022125598A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250067161A (ko) * 2022-09-14 2025-05-14 스핏파이어 파마, 엘엘씨 Glp-1r 및 gcgr 효능제를 사용하여 지방간 질환을 앓는 피험체에서 체중을 감소시키기 위한 치료 요법 및 방법
WO2024098071A1 (en) * 2022-11-05 2024-05-10 Spitfire Pharma Llc Therapeutic regimens and methods for treatment of cardiovascular risk factors using a glp-1r and gcgr agonist
IL328182A (en) * 2023-11-06 2026-07-01 Gan & Lee Pharmaceuticals Co Ltd GLP-1 receptor agonist for weight loss
US20250288650A1 (en) * 2024-03-12 2025-09-18 Spitfire Pharma Llc Therapeutic Regimens and Methods for Reducing Body Weight and/or Serum Lipids using a GLP-1R and GCGR Agonist
CN118477048B (zh) * 2024-05-24 2024-12-17 山东泰合医药科技有限公司 一种布瑞哌唑缓释微球及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506442A (ja) * 2007-12-11 2011-03-03 コンジュケム バイオテクノロジーズ インコーポレイテッド インスリン分泌性ペプチド結合体の製剤
CN117582516A (zh) * 2014-05-28 2024-02-23 梅德瑞斯糖尿病有限责任公司 针对胰岛素抵抗的改良肽药物
SG10202109721PA (en) * 2016-03-10 2021-10-28 Medimmune Ltd Glucagon and glp-1 co-agonists for the treatment of obesity
AU2019205905B2 (en) * 2018-01-03 2024-12-12 Mederis Diabetes, Llc Improved peptide pharmaceuticals for treatment of NASH and other disorders
US12441776B2 (en) * 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations

Similar Documents

Publication Publication Date Title
JP2006515351A5 (cg-RX-API-DMAC7.html)
KR101174966B1 (ko) 철이 발병에 관여하는 간질환의 치료
JP2022521233A5 (cg-RX-API-DMAC7.html)
CN117355297A (zh) 用于诱导褐色脂肪生成的方法和组合物
KR20240032789A (ko) 시클로-히스프로를 유효성분으로 포함하는 비만 예방 또는 치료용 약제학적 조성물
JP2025518227A5 (cg-RX-API-DMAC7.html)
CN119584980A (zh) 使用mazdutide的治疗方法
RS52867B (sr) Kombinovana terapija glatiramer acetatom i razagilinom za lečenje multiple skleroze
JP7451413B2 (ja) 肥満の治療および体重管理のためのglp-1組成物
Wedemeyer et al. 96 weeks of pegylated-Interferon-alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study: 31
JP2023510609A (ja) Glp-1および/またはglp-1類似体、ならびにインスリンおよび/またはインスリン類似体を含む併用療法
JP2026016423A (ja) Glp-1の投薬レジメン
JP2004526760A5 (cg-RX-API-DMAC7.html)
JP7344422B2 (ja) 糖尿病予防・治療用の医薬品組成物及びその用途
CN106822152B (zh) 一种药物组合物及其应用
CN109999019B (zh) 肉豆蔻脑酸甲酯在制备预防或治疗代谢综合征或改善机体能量代谢的产品中的应用
JP3885135B2 (ja) C型又は非b非c型肝炎ウイルスによる肝機能異常の改善剤
US20250367215A1 (en) Pharmaceutical combination comprising a cholane derivative and a statin or ursodesoxycholic acid
JP5667565B2 (ja) 閉経期、ホルモン変動および関節炎と関連する症状を治療するための組成物および方法
HK40094446A (en) Glp-1 dosing regimen
KR20090103656A (ko) 섬유근육통 치료제
US20200268820A1 (en) Pharmaceutical composition and uses thereof
WO2024155828A1 (en) Uses of aminopyridines in the management of weight and satiety
CN120168610A (zh) 一种白细胞介素-13在促进肌肉损伤后修复中的应用
CN116712420A (zh) 一种花椒酰胺在制备治疗多发性硬化症的药物中的应用